Drugs / HIL-214
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06007781 | Aug 2023 → May 2024 | gastroenteritis | HilleVax | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT05972733 | Aug 2023 | gastroenteritis | HilleVax | Completed | No outcome recorded |
| Phase 2 | NCT02153112 | Jun 2015 → Jun 2018 | norovirus infectious disease | Takeda | Completed | No outcome recorded |
| Phase 2 | NCT02475278 | Feb → Apr 2015 | norovirus infectious disease | Takeda | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT05836012 | Jun 2023 → Jan 2024 | gastroenteritis | HilleVax | Completed | No outcome recorded |
| Phase 2/3 | NCT05281094 | Apr 2022 → Dec 2023 | gastroenteritis | HilleVax | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HIL-214 | “We conducted a dose-finding phase 2 study of the HilleVax bivalent virus-like particle (VLP) vaccine candidate (HIL-214) in two cohorts of children, 6-≤12 months and 1-≤4 years...” PMID 37140558 ↗ May 20235“Serum samples collected during the evaluation of an investigational norovirus vaccine (HIL-214 [formerly TAK-214]) were assayed” PMID 38864524 ↗ Dec 2024 |
| Known as | TAK-214 | “Serum samples collected during the evaluation of an investigational norovirus vaccine (HIL-214 [formerly TAK-214]) were assayed” PMID 38864524 ↗ Dec 2024 |
| Modality | Vaccine | “HilleVax bivalent virus-like particle (VLP) vaccine candidate (HIL-214)” PMID 37140558 ↗ May 2023 |
| Route | Intramuscular | “received intramuscular injections of four different HIL-214 formulations” PMID 37140558 ↗ May 2023 |